Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19105301 | 0.87 | TSHR (0.42) | TSHRTDP1CYP3A4MAPTCACNA1B | |
| SCHEMBL3607061 | 0.84 | ALDH1A1 (0.39) | TSHRTDP1ALDH1A1HSD17B10GAA | |
| SCHEMBL11393698 | 0.84 | TSHR (0.42) | TSHRTDP1CYP3A4MAPTCACNA1B | |
| SCHEMBL20954020 | 0.83 | TSHR (0.40) | TSHRTDP1CYP3A4MAPTCACNA1B | |
| SCHEMBL11668021 | 0.83 | TSHR (0.39) | TSHRTDP1CYP3A4MAPTCACNA1B | |
| SCHEMBL7975200 | 0.82 | TSHR (0.41) | TSHRTDP1CYP3A4MAPTCACNA1B | |
| SCHEMBL4773694 | 0.82 | ALDH1A1 (0.37) | TSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL5227219 | 0.82 | TSHR (0.32) | TSHRCYP3A4MAPT | |
| SCHEMBL32679948 | 0.81 | TSHR (0.43) | TSHRTDP1CYP3A4MAPTCACNA1B | |
| Acetic Acid SCHEMBL28822001 | 0.81 | MMP8 (0.37) | TSHRTDP1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613606-A4 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMA INC (US) | 2008-12-03 | — | — | EP | claimed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | claimed |
| EP-1613606-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004092121-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | TYMP, DPYD, DHFR | TSHR 3414/4885TDP1 637/4885CYP3A4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.